Matrix metalloproteinase expression in high grade soft tissue sarcomas

Oncology Reports

Volumn 18, Issue 6, 2007, Pages 1529-1536

  Alford, Stephanie H ^a   Vrana, Michael S ^a   Waite, Lindsay ^a   Heim Hall, Josefine ^b   Sylvia, Victor L ^a   Williams, Ronald P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

High grade soft tissue sarcomas; Liposarcoma; Matrix metalloproteinases; MFH; MMPs; Synovial sarcoma

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BIOPSY; CONNECTIVE TISSUE TUMOR; ENZYMOLOGY; HUMAN; LIPOSARCOMA; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SARCOMA; SURVIVAL; TIME;

BIOPSY; HUMANS; LIPOSARCOMA; RETROSPECTIVE STUDIES; SARCOMA; SARCOMA, SYNOVIAL; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 38449113602     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.6.1529     Document Type: Article

References (28)

1. Pollock R: Soft tissue sarcomas. American Cancer Society Atlas of Clinical Oncology. BC Decker, London, 2002.
2. Gustafson P: Soft tissue sarcoma: epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259: 1-31, 1994.
3. Campanacci M: Bone and Soft Tissue Tumors. 2nd edition. Piccin Nuova Libraria, Padova, 1999.
4. American Cancer Society: Cancer Statistics 2006. http://www.cancer.org/
5. Fletcher C, Unni K and Mertens F (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon, 2002.
6. Cormier J: Soft tissue sarcomas. CA Cancer J Clin 54: 94-109, 2004.
7. Ham S, van der Graaf W, Pras E., Molenaar W, van den Berg E and Hoekstra H: Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. Cancer Treat Rev 24: 373-391, 1998. (Pubitemid 29121678)
8. Takey M, Yoshimura T, Leonard E, Kato T, Okabe H and Takahashi K: Production of monocyte chomattractacnt protein-1 by malignant fibrous histiocytoma: relation to the origin of histiocyte-like cells. Exp Mol Pathol 54: 61-71, 1991
9. Kartha S and Bumpous J: Synovial cell sarcoma: diagnosis, treatment, and outcomes. Laryngoscope 112: 1979-1982, 2002. (Pubitemid 35283459)
10. Pisters P: Staging and prognosis. In: American Cancer Society Atlas if Clinical Oncology: Soft Tissue Sarcomas. Pollock RE (ed). BC Decker, Inc., Hamilton, Ontario, pp80-88, 2002.
11. Cawley LJ and Matrisian LM: Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13: 534-540, 2001. (Pubitemid 32817010)
12. Delaisse J, Engsig M, Everts V, Overejo M, Ferreras M, Lund L, Vu T, Werb Z, Winding B, Lochter A, Kardsal M, Troen T, Kirkegaard T, Lenhard T, Heegaard N, Neff L, Baron R and Foged N: Proteinases in bone resorption: obviousand less obvious roles. Clin Chim Acta 291: 223-234, 2000.
13. Mandal M, Mandal A, Das S, Chakraborti T and Chakraborti S: Clinical implications of matrix metalloproteinases. Mol Cell Biochem 252: 305-329, 2003. (Pubitemid 37220762)
14. Papathoma A, Zoumpourlis V, Balmain A and Pintzas A: Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol Carcinog 31: 74-82, 2001.
15. Nemeth J, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R and Cher M: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94: 17-25, 2002. (Pubitemid 34082839)
16. Nelson A, Fingelton B, Rothenberg M and Matrisian L: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
17. Roebuck MM, Helliwell TR, Chaudhry IH, Kalogrianitis S, Carter S, Kemp GJ, Ritchie DA, Jane MJ and Frostick SP: Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 123: 405-414, 2005. (Pubitemid 40315082)
18. Godfrey T, Kim S, Chavira M, Ruff D, Warren R, Gray J and Jensen R: Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative transcription polymerase chain reaction. J Mol Diagn 2: 84-91, 2000.
19. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
20. Semaan M, Jovenin N, Birembaut P, Menard J and Staerman F: Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer. Prog Urol 15: 250-254, 2005. (Pubitemid 41502579)
21. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33: 44-50, 2005. (Pubitemid 40487192)
22. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J and Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25: 3387-3391, 2005. (Pubitemid 41105215)
23. Langenskiold M, Holmdahl L, Falk P and Ivarsson ML: Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis 20: 245-252, 2005. (Pubitemid 40553003)
24. Moran A, Iniesta P, Garcia-Aranda C, De Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL and Benito M: Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 13: 115-120, 2005.
25. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole B, Zucker S and Birembaut P: EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 19: 697-702, 2002. (Pubitemid 36092265)
26. Davidson B, Goldberg I, Berner A, Kristensen G and Reich R: EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 20: 161-169, 2003. (Pubitemid 36403281)
27. Benassi MS, Gamberi G, Magagnoli G, Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini M, Bertoni F, Mercuri M and Picci P: Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 12: 75-80, 2001. (Pubitemid 32162450)
28. Maguire PD, Qi WN, Lallemand R and Scully S: Gelatinase and inhibitor expression in soft tissue sarcomas:lack of correlation with distant metastasis. Oncology 59: 139-144, 2000.